Extracellular Vesicle-Mediated Drug Delivery and Uptake in GFP-Tagged MDA-MB-231 Spheroids: A 3D Fluorescence-Based Theranostic Model

Kriti Awasthi*, Ewa Stępień** and Magdalena Kostkiewicz***

*Doctoral School of Medical and Health Sciences, Jagiellonian University Collegium Medicum, Kraków, Poland. **Faculty of Medical Physics, Jagiellonian University; Centre Of Theranostics, Kraków, Poland

***Heart and Vascular Disease Clinics, Jagiellonian University Collegium Medicum Kraków, Poland.





Extracellular vesicles (EVs) have emerged as critical mediators of intercellular communication in cancer, carrying proteins, nucleic acids, and lipids that influence tumour progression and therapeutic response. Traditional two-dimensional (2D) cultures fail to capture the spatial and biochemical complexity of tumours, whereas three-dimensional (3D) spheroid models more accurately reproduce in vivo conditions, including gradients of oxygen, nutrients, and extracellular matrix interactions.

Fluorescence-based tracking provides a powerful approach to study EV uptake, distribution, and penetration in these 3D systems. Such visualisations are essential for developing strategies to engineer EVs as targeted drug delivery vehicles. Importantly, integrating fluorescence analysis with positron emission tomography (PET)—compatible probes can bridge preclinical discoveries with clinical imaging, enabling real-time monitoring of EV behaviour in vivo.

This study applies fluorescence-guided imaging to examine the dynamics of EV interaction with breast cancer spheroids, aiming to generate insights that inform the development of PET-compatible theranostic platforms.





Fig. 1: Representative images of MDA-MB-231 GFP (A) and Control cells (B) and spheroids (C , D and E). GFP-expressing spheroids form more loosely associated, cluster-like structures (C). The GFP fluorescence signal highlights the distribution of GFP-positive cells (D) within the spheroid architecture, while Control spheroids (E) display a compact, well-organized morphology. Scale: $500 \, \mu m$

2. Methodology


a) 3D cell culture (Spheroids)






3D culture devices (Celvivo®)

MDA-MB-231 cells were expanded in 2D, then cultured in CelVivo® (A) clinostat bioreactors (B) to form scaffold-free spheroids. Control spheroids developed compact structures, while GFP-expressing spheroids formed loose clusters. Mature spheroids after 14 days isolated EV's from GFP- expressing spheroids, followed by NTA, after attaining desired concentration, they were stained with PKH26 and incubated with controls for 24 hrs followed by imaging to evaluate EV secretion, uptake, and distribution over time.




MDA MB 231 - GFP EVs visualisation through nanoparticle tracking analysis (refer figure C)



A single GFP-EV picturization

Staining with PKH26 red fluorescent dye (refer figure D / E)

PKH26 is a lipophilic fluorescent dye widely used to label extracellular vesicles (EVs) for uptake and tracking studies. In this study, EVs were stained using PKH26 at a final concentration of approximately 1 µg/mL for 24 hrs (refer Figure D and E). This working concentration enabled the reliable visualisation of EVs without compromising particle integrity or introducing excessive free-dye artefacts.



4. Conclusion

This study demonstrates that fluorescence-based imaging in 3D spheroid models enables precise visualization of EV uptake and distribution, capturing the complex tumor microenvironment more effectively than 2D systems. The results highlight distinct EV secretion and uptake dynamics in GFP-expressing versus control spheroids, underscoring the influence of tumor heterogeneity. Importantly, these findings establish a foundation for integrating fluorescence guided assays with PET-compatible probes, paving the way for translational theranostic platforms. Such dual modality approaches hold significant promise for advancing EV-based drug delivery, enabling real-time, non-invasive monitoring from bench to bedside.

3. Results

 $500 \, \mu m$

500 μm

B

D




Fig. 3.A: The bar chart demonstrates reduced EV yield from GFP-expressing spheroids relative to controls, suggesting that **GFP** expression altered and spheroid morphology may EV impact secretion dynamics.

Labeling

EV

• PKH26 at 1 μ g/mL \rightarrow strong, stable fluorescence

Size distribution preserved; minimal aggregation

NTA Analysis

- Particle concentration: 10⁷–10⁸ particles/mL
- Control spheroids: 3.57×10⁸ particles/mL
- GFP spheroids: 1.45×10⁸ particles/mL
- Vesicle integrity maintained

Spheroid Uptake

- Fig. B: Control spheroids → compact, solid structure
- Fig. C: PKH26-labeled EV uptake → localized penetration
- Fig. D: Masked imaging (3500 μs, red channel)
 clear EV spatial distribution
- ullet GFP spheroids o loose, cluster-like morphology; heterogeneous uptake

Impact

- Robust EV tracking in 3D tumor models
- Supports fluorescence-guided monitoring
- Foundation for PET-compatible theranostics

5. References

- 1. Hanieh Karimi, Paweł Moskal, Ewa Ł. Stępień, 3D melanoma spheroid model for the development of positronium biomarker, bioRxiv 2022.06.01.494339 (2022)
- 2. Stepien, Ewa & Karimi, Hanieh & Leszczynski, Bartosz & Szczepanek-Dulska, Monika. (2020). Melanoma Spheroids as a Model for Cancer Imaging Study. Acta Physica Polonica B. 51. 159. 10.5506/APhysPolB.51.159.
- . Moskal, P., Jasińska, B., Stępień, E.Ł. et al. Positronium in medicine and biology. Nat Rev Phys 1, 527–529 (2019).

OPUS grant from NCN:2022/45/B/NZ7/01430 for Ewa Stępień and qLife Priority Research Areas budget under the program Excellence Initiative Research University at the Jagiellonian University Flagship Project Center for Theranostics

Acknowledgement

Uniwersytet Jagielloński providing funding for Kriti Awasthi from Ministry of Science and Higher Education competition "Initiative of Excellence - Research University" - IDUB in accordance to support young researchers.